The challenges identified in the report include such issues as heterogeneity in disease presentation and patient experience, poor/incomplete understanding of disease natural history, identifying concepts of interest for meaningful treatment benefit given patient heterogeneity, access to patients and caregivers, concept saturation, psychometric validation, and linguistic validation when developing or adapting an instrument. As the authors point out, many of these challenges are not necessarily unique to rare disease trials, but because of the small population sizes, these challenges are magnified in rare disease research. Indeed many of the challenges under each of the roadmap headers appear to overlap quite significantly, largely driven by the issues of patient and disease heterogeneity and access to patients (small sample sizes).
Many sensible and pragmatic solutions are proposed in the report and some clear advice regarding engagement with advocacy groups is presented. However, many of these solutions appear to be based on common practices applied outside rare disease settings simply because of sample or time constraints, and there is a sense that applying the structure of the roadmap has constrained exploration of potentially novel methodological approaches. There may be benefit in thinking more broadly and creatively about alternative methods of demonstrating treatment benefit or capturing COA data in rare diseases in which the sample sizes may render more traditional statistical approaches difficult to interpret or inappropriate. Extending this consideration of methodological approaches to define benefit or value to the economic or value assessment domain may assist with the need for more creative thinking and would also be a good next step for this task force.
Other solutions presented in the report appear to rely on sample sizes that may be problematic in rare disease, such as conducting sensitivity analysis, stratifying samples by prognostic factors, or increasing the amount of qualitative work to support quantitative outcomes. The authors are very clear from the outset that these proposed solutions are not a "one size fits all" for rare disease clinical trials. These examples may be clear cases of this, but some of the suggested solutions actually raise interesting questions that would be worthwhile exploring in further work from this task force. For example, the suggestions to consider individualized outcomes or to use multiple versions of a patient-reported outcome with similar concepts are both likely to bring additional challenges (both conceptually and statistically), but would be worth considering further in our efforts to identify a meaningful end point when the sample is very heterogeneous.
In conclusion, the work of the task force to highlight challenges and start to explore solutions associated with COAs in rare diseases is essential to ensuring that relevant and meaningful patient outcomes are adequately captured in clinical trials of rare disease. The current report provides a comprehensive account of challenges related to clinical trial end points and offers numerous suggested solutions to these challenges. Extending this work to include a deeper exploration of some methodological options and statistical approaches that also incorporates the economic/payer needs would result in a broader consideration of measuring benefit in rare disease and may also lead to novel approaches to COA or benefit measurement that may further address the challenges raised.
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